NEW YORK, Nov. 19, 2015 (GLOBE NEWSWIRE) -- LifeSci Advisors, LLC, (the "Company" or "LifeSci") an investor relations and corporate communications firm focused on the life sciences sector, today announced the appointment of Bob Yedid as Managing Director.
Mr. Yedid joins LifeSci from ICR, LLC, where he provided medtech, diagnostics and specialty pharmaceutical companies ongoing investor relations advice as well as advisory services related to public and private securities offerings, mergers and acquisitions, and C-suite executive transitions. Prior to joining ICR, Mr. Yedid spent 10 years as Portfolio Manager and Senior Research Analyst, with responsibility for all healthcare investing, at Principled Capital, a fund with $1.5 billion of AUM. Prior to Principled, he was a Vice President at Warburg Pincus, one of the world's largest private equity and venture capital firms, investing in health care. He also spent 15 years in investment banking, including serving as Managing Director in Healthcare Corporate Finance Group at Bear Stearns & Co., having worked on capital markets and M&A transactions in excess of $5.0 billion. Bob earned a BA in Economics from Yale University and an MBA from Stanford University Graduate School of Business.
"Bob's unique blend of significant experience in both financial services and investor relations with a focus on healthcare makes him a perfect fit for our team," said Michael Rice, President at LifeSci Advisors. "Bob will provide senior counsel to our clients and play an important role at our firm."
LifeSci Advisors has more than doubled its headcount in the last 12 months across all aspects of its business. Recent key hires include Hans Vitzthum, Matthew Duffy, and Brian Ritchie. Messrs. Vitzthum, Duffy, and Ritchie have a combined 70 years of experience in the life sciences sector.
Mr. Vitzthum has more than 25 years of experience in institutional sales and healthcare research product management at Leerink Partners, Cowen & Co., and Lazard Capital Markets. Mr. Vitzthum has worked in healthcare research product management for the past 15 years and has developed extensive and long-standing relationships with the institutional investor community.
Mr. Duffy has extensive development-to-market experience as a life science executive having led the efforts to bring several important new drugs to commercialization including Synagis (MedImmune) and Cinryze (Lev Pharmaceuticals). Mr. Duffy has spent nearly 15 years as a buy-side and sell-side equity research analyst and investment banker.
Mr. Ritchie joined LifeSci from FTI Consulting, where he worked for eight years as Senior Director within the Strategic Communications segment's Capital Markets practice and life sciences sector. Overall, Mr. Ritchie has over 15 years of healthcare investor communications experience. He focuses on developing, implementing and overseeing investor relations programs for leading medical technology, biotechnology, specialty pharmaceutical, and healthcare services companies.
About LifeSci Advisors, LLC
LifeSci Advisors is a unique investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. With local presence in New York, Boston, Chicago, and Geneva, the firm provides the highest quality service for its clients through its deep sector specialization. Our roster of Ph.D.s enables us to better understand our clients' R&D, regulatory, and commercial strategy, and our team of financial services, investor relations, and public relations specialists help our clients effectively communicate their strategies to the marketplace. This combination of life sciences, financial services, and investor relations expertise allows us to provide a valuable and unique service offering to our clients.
Visit our website: